Evidence map›Paper›PMID 27809845›Full record

ArticleCardiovascular diabetology2016

Impact of diabetes on the predictive value of heart failure biomarkers.

Nuria Alonso, Josep Lupón, Jaume Barallat, Marta de Antonio, Mar Domingo, Elisabet Zamora, Pedro Moliner, Amparo Galán, Javier Santesmases, Cruz Pastor and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cardiovascular diabetology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Nuria AlonsoHeart Failure Clinic, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain.ORCID 0000-0001-5844-2221
Josep LupónHeart Failure Clinic, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain.
Jaume BarallatDepartment of Biochemistry, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Marta de AntonioHeart Failure Clinic, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain.
Mar DomingoHeart Failure Clinic, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain.
Elisabet ZamoraHeart Failure Clinic, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain.
Pedro MolinerHeart Failure Clinic, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain.
Amparo GalánDepartment of Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Javier SantesmasesHeart Failure Clinic, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain.
Cruz PastorDepartment of Biochemistry, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Dídac MauricioDepartment of Endocrinology and Nutrition, CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona, Spain. didacmauricio@gmail.com.
Antoni Bayes-GenisHeart Failure Clinic, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain. abayesgenis@gmail.com.
Universitat Autònoma de Barcelona · ESCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESHospital Universitari Germans Trias i Pujol · ESMarqués de Valdecilla University Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with diabetes mellitus (DM) have an increased risk of developing heart failure (HF). Further, DM is associated with poor prognosis in patients with HF. Our aim was to determine whether DM has any impact on the predictive value of a multi-biomarker panel in patients with HF.

methodsWe included 1069 consecutive ambulatory HF patients in the study: age 66.2 ± 12.8 years, 33.5 ± 13.3 left ventricular ejection fraction, 36% diabetic patients. We measured serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), ST2, galectin-3, high-sensitivity C reactive protein (hs-CRP), cystatin-C, soluble transferrin receptor (sTfR), and neprilysin and followed patients for 4.9 ± 2.8 years. Primary endpoints were all-cause and cardiovascular death.

resultsDuring follow-up, 534 patients died; 283 died of cardiovascular causes. Diabetic subjects had higher mortality (57.7 vs. 45.6%, p < 0.001). NTproBNP (p = 0.07), hs-TnT (p < 0.001), galectin-3 (p < 0.001), and cystatin-C (p = 0.001) concentrations were higher in diabetic patients, whereas sTfR levels were lower (p = 0.005). There were no interactions between DM and NTproBNP, hs-TnT, galectin-3, hs-CRP, cystatin-C, sTfR, and neprilysin relative to risk prediction for all-cause or cardiovascular death. By contrast, ST2 significantly interacted with DM for all-cause (p = 0.02) and cardiovascular (p = 0.03) death. In diabetic patients, HRs for ST2 were 1.27 (95% CI 1.16-1.40, p < 0.001) and 1.23 (95% CI 1.09-1.39, p = 0.001) for all-cause and cardiovascular death, respectively. In nondiabetic patients, HRs for ST2 were 1.53 (95% CI 1.35-1.73, p < 0.001) and 1.64 (95% CI 1.31-2.05, p < 0.001) for all-cause and cardiovascular death, respectively. The multivariable Cox regression analysis showed that hs-TnT and ST2 were the only markers that were independently associated with both all-cause and cardiovascular mortality in patients with HF and diabetes. Moreover, in these patients, the combination of these two markers significantly increased discrimination as assessed by the area under the curve.

conclusionsBiomarkers used in the general population to predict the clinical course of heart failure are also useful in patients with diabetes. In these patients, among all the biomarkers analysed only hs-TnT and ST2 were independently associated with both all-cause and cardiovascular mortality.

Indexed as

AgedBiomarkersCause of DeathChi-Square DistributionDiabetes Mellitus, Type 2FemaleHeart FailureHumansInterleukin-1 Receptor-Like 1 ProteinMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsPrognosisProportional Hazards ModelsRisk AssessmentBiomarkersIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinTroponin TBiomarkersDiabetes mellitusHeart failurePrognosticST2

Identifiers

PMID27809845
PMCPMC5093972
OpenAlexW2548455412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.